老年人膜性肾病临床诊治的进展  

Progress in the treatment of elderly patients with primary membranous nephropathy

作　　者：柏云[1] 裴小华[1] 赵卫红[1] Bo Yun;Pei Xiaohua;Zhao Weihong(Division of Nephrology,Department of Geriatrics,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院老年肾科,210029

出　　处：《中华老年医学杂志》2021年第10期1234-1237,共4页Chinese Journal of Geriatrics

基　　金：国家重点研发计划(2018YFC2002100、2018YFC2002102);江苏省医学重点学科(ZDXKA2016003);江苏省医学人才项目(ZDRCA2016021);江苏省干部保健课题(BJ17018);江苏省人民医院511工程(JSPH-511A-2018-5)。

摘　　要：膜性肾病(MN)是老年人肾病综合征的主要原因,近年来发病率逐年增加。随着抗磷脂酶A2抗体(PLA2R)等的发现,MN的诊治也进入了新的分子时代。本文结合2020年改善肾脏病预后全球组织(KDIGO)发布的指南对MN的临床诊治进展进行综述。Membranous nephropathy(MN)is the most common cause of nephrotic syndrome in the elderly.In recent years,the prevalence of MN has been increasing every year.The diagnosis and treatment of MN has entered the new era of molecular medicine with the identification of autoantibodies against the phospholipase A2 receptor(PLA2R).This review focuses on recent advances in the treatment and diagnosis of MN based on the 2020 Kidney Disease:Improving Global Outcomes(KDIGO)guidelines.

关 键 词：肾小球肾炎 膜性 磷脂酶A2 

分 类 号：R692[医药卫生—泌尿科学]